• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Alexion Pharmaceuticals Does Not Look Boston Strong

Charts of the Boston-based biotech to do not provide a compelling case to buy the stock.
By BRUCE KAMICH
Nov 22, 2019 | 11:38 AM EST
Stocks quotes in this article: ALXN

The Lightning Round is a very popular segment of Jim Cramer's Mad Money program. Callers get the chance to ask Jim about stocks they are interested in. Thursday night one caller asked about Boston-based Alexion Pharmaceuticals Inc. (ALXN) : "This valuation is too high. It's not my favorite," replied Cramer. 

Let's check out the charts of ALXN to see what they can add to the conversation.

In the daily bar chart of ALXN, below, we can see that the prices were in a declining phase from April to September/October. Prices have shown some improvement into November but the pattern of lower highs is still intact. Prices are trading between the slightly rising 50-day moving average line and the slightly declining 200-day moving average line.

The daily On-Balance-Volume (OBV) line has been weak from July and tells us that sellers of ALXN have been more aggressive -- this is not what chart watchers want to see. The 12-day price momentum study shows a small bearish divergence from October to November as momentum weakened slightly. 

 
In the weekly bar chart of ALXN, below, we see a mixed picture with the price action and the indicators. Prices are below the declining 40-week moving average line.
 
The weekly OBV line shows are on the rise the past four months, signaling more aggressive buying while the Moving Average Convergence Divergence (MACD) oscillator has crossed to the upside for a cover shorts buy signal. 
 
 
In this Point and Figure chart of ALXN, below, we can see a potential upside price target of $125 and that a trade at $104.44 could weaken this chart. 
 
 
 
Bottom-line strategy: These three charts of ALXN do not yet provide a compelling case to go long.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Pharmaceuticals | Mad Money

More from Stocks

It's Big-Cap AI Stocks Vs. Everything Else

James "Rev Shark" DePorre
May 30, 2023 4:35 PM EDT

The biggest problem now is that the big-cap names are not acting as leaders.

Beyond Meat and Peloton: Zombie Stocks Can Turn Portfolios Into the Walking Dead

Brad Ginesin
May 30, 2023 3:30 PM EDT

Don't confuse a stock revival masquerading as a living, breathing business revival.

In Case You Missed It: Apple Just Hit a New 52-Week High

Bruce Kamich
May 30, 2023 2:45 PM EDT

Let's not ignore the strength in AAPL.

Bristol-Myers Squibb Breaks a Key Support Area: What's Next?

Bruce Kamich
May 30, 2023 12:50 PM EDT

Here's what the charts and indicators say.

Here's the Truth About Oil No One Saw, as OPEC+ Takes the Stage

Maleeha Bengali
May 30, 2023 12:32 PM EDT

Let's look at what many observers failed to notice about oil, and what could happen when the oil exporting nations -- including Russia -- meet on June 4.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:48 AM EDT CHRIS VERSACE

    Latest AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • 03:25 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Don't Just Sit There and 'Hope' for Your Stocks, M...
  • 07:32 AM EDT BOB LANG

    Webinar Thursday After the Close: Option Spread Trading

    Thursday, my good friend and colleague Sam DeMarco...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login